Trial Profile
Post-marketing surveillance for acute Kawasaki Disease under Remicade treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Mucocutaneous lymph node syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms SAKURA study
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 01 Jan 2020 Results published in the Pediatric Infectious Disease Journal
- 04 Jan 2019 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Status changed from recruiting to active, no longer recruiting.